Quote:

---

UAMS Research Team Finds Potential Cause of COVID-19 ‘Long-haulers’
https://news.uams.edu/2021/09/09/uams-researc...g-haulers/

---

A tip of the hat to swordman for posting the link originally.

If they are correct about the reason for longhaulers and Sars-COV2 induced antibodies are destroying the ACE receptor cells then leronlimab could be of help. ACE2 keeps the Renin Angiotensin Aldesterone system (RAS) in check. Overproduction of RAS leads to a hyper-inflammatory state through the Ras/Raf/MEK/ERK/NF-κB signaling pathway. Binding of CCL5 (RANTES) to CCR5 activates the Gai-Gby complex which in turn increases the production of RAS.

Leronlimab by blocking CCL5 would reduce RAS production and lessen the inflammatory state. Additionally leronlimab would block the cytokines.

Why some are getting longhaulers and others are not could come down to genetics. In a different disease (Henoch–Schönlein purpura) it's been shown that a combination of genetic variations in CCL2, VEGF and the ACE receptor are significantly more likely to cause the disease. Genetic variation may also explain why in a small number of longhaulers cases leronlimab is not effective.

https://advances.umw.edu.pl/pdf/2017/26/4/661.pdf